WHO Approves First Monkeypox Vaccine for Emergency Use
Geneva, Switzerland – The WorldHealth Organization (WHO) announced on September 13, 2024, thatit has granted an Emergency Use Listing (EUL) to the monkeypox vaccine produced by Bavarian Nordic, a Danish pharmaceutical company. This marks the first vaccine approvedby the WHO for use against the ongoing monkeypox outbreak.
The EUL allows for the vaccine to be used in countries facing monkeypox outbreaks, particularly those withlimited access to healthcare resources. The vaccine, known as Jynneos in the United States and Imvanex in Europe, is a two-dose regimen for individuals aged 18 years and older, with a four-week interval between doses.
This is a significant step forward in the global fight against monkeypox, said Dr. Tedros Adhanom Ghebreyesus, WHO Director-General. This vaccine has the potential to save lives and protect people fromthis devastating disease.
The WHO’s decision comes after a surge in monkeypox cases globally, with the virus spreading to over 100 countries since the start of 2022. The outbreak has disproportionately affected men who have sex with men, raising concerns about stigma and discrimination.
TheEUL is based on a comprehensive review of the vaccine’s safety, efficacy, and quality. The vaccine has been shown to be highly effective in preventing monkeypox infection, with a reported efficacy of over 85% in clinical trials.
This EUL is a testament to the collaborative efforts of scientists,regulators, and public health officials around the world, said Dr. Sylvie Briand, Director of the WHO’s Department of Immunization, Vaccines, and Biologicals. We are committed to ensuring that this vaccine is available to those who need it most.
The WHO’s approval is expected to accelerate the globalresponse to the monkeypox outbreak. The organization has been working closely with countries to develop and implement vaccination strategies, including prioritizing high-risk groups and ensuring equitable access to the vaccine.
However, challenges remain in the fight against monkeypox. The vaccine supply is currently limited, and there is a need for increased productionto meet the growing demand. Additionally, efforts are underway to develop new vaccines and treatments, as well as to improve surveillance and public health messaging.
The WHO’s approval of the first monkeypox vaccine is a crucial step towards controlling the outbreak and protecting vulnerable populations. The organization is committed to working with partners to ensurethat everyone has access to the tools they need to prevent and treat monkeypox.
Background on Monkeypox
Monkeypox is a viral disease that is spread through close contact with an infected person or animal. Symptoms include fever, rash, headache, muscle aches, and swollen lymph nodes. The disease is typicallymild, but it can be fatal in some cases.
The current monkeypox outbreak is the largest and most widespread ever recorded. The virus is believed to have originated in Central and West Africa, but it has now spread to all continents.
Importance of Vaccination
Vaccination is a crucial tool for preventingand controlling monkeypox outbreaks. The vaccine is particularly important for individuals who are at high risk of exposure, such as healthcare workers, laboratory personnel, and people who have close contact with infected individuals.
The WHO recommends that countries prioritize vaccination for high-risk groups and ensure that the vaccine is available to all who need it.
Conclusion
The WHO’s approval of the first monkeypox vaccine is a significant milestone in the global response to the outbreak. The vaccine has the potential to save lives and protect people from this devastating disease. However, challenges remain, including limited vaccine supply and the need for continued research and development. The WHO is committedto working with partners to ensure that everyone has access to the tools they need to prevent and treat monkeypox.
Views: 0